Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 20,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood sample Clear all
Completed No phase listed Observational Accepts healthy volunteers

Laser Fluorescent Imaging of Nipple and Areola During Breast Lift

NCT02201979
View directory record Official record
Conditions
Breast Sagging, Ptosis, Loss of Breast Volume
Interventions
Vertical breast lift with implants
Procedure
Lead sponsor
Swanson Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 20, 2026, 4:49 AM EDT
Completed Phase 4 Interventional Results available

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

NCT00420927
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
adalimumab, methotrexate, placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 20, 2026, 4:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

OSA in Pregnant Women With Chronic HTN

NCT03230110
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Pregnancy, Hypertension
Interventions
WP200U home sleep study device
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 20, 2026, 4:49 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

BFR Therapy in Patients With Rotator Cuff Tears

NCT04384120
View directory record Official record
Conditions
Blood Flow Restriction
Interventions
Blood Flow Restriction Therapy, Traditional Therapy
Device · Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 20, 2026, 4:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adaptive Preventive Intervention for College Alcohol Use

NCT03930524
View directory record Official record
Conditions
College Student Drinking
Interventions
Personalized Normative Feedback (PNF), Self-Monitoring (SM), Web-BASICS, Health Promotion Consultation, M-Bridge Online Health Coach
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 21 Years
Enrollment
891 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 20, 2026, 4:49 AM EDT
Completed Phase 4 Interventional Results available

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

NCT01119859
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Adalimumab, Placebo to tocilizumab, Placebo to adalimumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 20, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus

NCT00850096
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo for Nasulin, Nasulin
Other · Drug
Lead sponsor
CPEX Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Chandler, Arizona • Escondido, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 20, 2026, 4:49 AM EDT
Recruiting No phase listed Observational

A Study of Glycemic Control in Left Ventricular Assist

NCT05933161
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions
Freestyle Libre 3 Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 4:49 AM EDT
Completed Phase 1 Interventional

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

NCT04164069
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma
Interventions
Bevacizumab, Dasatinib, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Anne Noonan
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 20, 2026, 4:49 AM EDT
Completed No phase listed Observational

Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202

NCT01503619
View directory record Official record
Conditions
Lung Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 20, 2026, 4:49 AM EDT
Terminated Phase 3 Interventional Results available

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

NCT01031628
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib mesylate
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • Santa Monica, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Oct 20, 2026, 4:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program

NCT00969865
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 20, 2026, 4:49 AM EDT
Recruiting Phase 4 Interventional

PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy

NCT06915792
View directory record Official record
Conditions
Postpartum Hypertension (PPHT)
Interventions
Labetalol, Nifedipine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 20, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

NCT04382664
View directory record Official record
Conditions
Malignant Melanoma
Interventions
UV1, Sargramostim, Ipilimumab, Nivolumab
Biological
Lead sponsor
Ultimovacs ASA
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 20, 2026, 4:49 AM EDT
Completed No phase listed Observational

Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation

NCT01581164
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant
Interventions
Influenza vaccine, Varicella vaccine
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
5 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 20, 2026, 4:49 AM EDT
Not listed No phase listed Observational

Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)

NCT03053999
View directory record Official record
Conditions
Multiple Endocrine Neoplasia, Pancreatic Neuroendocrine Tumors, Hyperparathyroidism
Interventions
Genome Sequencing, Data Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 20, 2026, 4:49 AM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection

NCT00000663
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 5 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional Results available

Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

NCT00418093
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Gemcitabine, Oxaliplatin, Bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 20, 2026, 4:49 AM EDT
Terminated Phase 1 Interventional Results available

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

NCT02954406
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
TAK-659, Bendamustine, Rituximab, Gemcitabine, Lenalidomide, Ibrutinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Tucson, Arizona • La Jolla, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 20, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Real-time Adaptation to Changes in Insulin Sensitivity

NCT01261052
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm, The Adaptive Proportional Derivative Algorithm
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 20, 2026, 4:49 AM EDT
Active, not recruiting No phase listed Observational

Serum Neurofilament Light in Multiple Sclerosis

NCT06282081
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Interventions
Serum Neurofilament Light
Diagnostic Test
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 20, 2026, 4:49 AM EDT
Active, not recruiting Phase 1 Interventional

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

NCT06445907
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax, Q702
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 4:49 AM EDT
Terminated Not applicable Interventional

Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation

NCT02205411
View directory record Official record
Conditions
Heart Failure, Cardiac Failure, Congestive Heart Failure, Heart Failure, Left-sided
Interventions
HeartAssist 5® VAD System, Control VAD
Device
Lead sponsor
ReliantHeart Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
San Francisco, California • Stanford, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 20, 2026, 4:49 AM EDT
Completed Not applicable Interventional

Remote Monitoring in Diabetes Disease Management

NCT00675311
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
DM-Standard, Disease Management Plus
Behavioral
Lead sponsor
LifeScan
Industry
Eligibility
18 Years to 64 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2009 · Synced Oct 20, 2026, 4:49 AM EDT